Skip to contentP
Phathom Pharmaceuticals, Inc.
P
PHATPhathom Pharmaceuticals, Inc. Q2 2025 · 10-Q
Revenue$39.50M$39.50M+439.4% vs Q2 2024 Net Income-$75.81M-$75.81MN/M vs Q2 2024 EPS Diluted-$1.05-$1.05N/M vs Q2 2024 Gross Profit$34,465,000+479.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Phathom Pharmaceuticals, Inc. · CIK 1783183 · Engraved from SEC EDGAR
Operating Cash Flowderived-$62,729,000N/M Free Cash Flowderived-$62,826,000N/M Margins · derivedGross margin87.2%+6.0 pt vs Q2 2024
Operating margin-151.7%+903.7 pt vs Q2 2024
Net margin-191.9%+1056.7 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 7, 2025 · 38 d after period end